Results 101 to 110 of about 5,445 (182)

Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH

, 2016
An 11-year-old boy developed severe syndrome of inappropriate antidiuretic hormone secretion (SIADH) after diagnosis of an intracranial B-cell lymphoma. His sodium levels dropped to 118–120 mmol/L despite 70% fluid restriction.
Thankamony, Ajay, Burke, G A Amos; id_orcid, Willemsen, Ruben H, Violeta Delgado-Carballar, Elleri, Daniela, Dunger, David B, Ruben H Willemsen, Delgado-Carballar, Violeta, G A Amos Burke, Nicholson, James C, Daniela Elleri, David B Dunger, Ajay Thankamony, James C Nicholson   +13 more
core   +1 more source

Sulfonate and acetyl derivatives of the vasopressin antagonist tolvaptan: reactivity towards DNA and 2’-deoxynucleosides [PDF]

, 2015
Tolvaptan is an orally effective nonpeptide arginine vasopressin (AVP) V2-receptor antagonist, used in the treatment of clinically significant euvolemic and hypervolemic hyponatremia.
Fidalgo, Lara Gião
core  

Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure

Although reports suggest that tolvaptan does not reduce survival or subsequent hospitalization rates in heart failure patients, its continuous use has shown good outcomes in some patients who cannot be effectively managed with high doses of loop ...
Ishii, Hideki, Osanai, Hiroyuki, Ajioka, Masayoshi, Ogawa, Hayato, Murase, Yosuke, Asano, Hiroshi, Okumura, Takahiro, Nakasima, Yoshihito, Sakai, Kazuyoshi, Murohara, Toyoaki   +9 more
core  

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan

Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2.
Onishi, Hideki, Wada, Nozomu, Okada, Hiroyuki, Takeuchi, Yasuto, Adachi, Takuya, Shiraha, Hidenori, Oyama, Atsushi, Takaki, Akinobu   +7 more
core   +1 more source

Successful treatment of chronic alcohol-induced refractory hyponatremia with tolvaptan: a case report with in-depth analysis of traditional treatment failure mechanisms. [PDF]

Front Pharmacol
Yan K, Zhou J, Zeng H, Liu D, Tao W, Fang Z, Yang X.   +6 more
europepmc   +1 more source

Paradoxical Hyponatremia on High-Dose Tolvaptan in ADPKD. [PDF]

Kidney Int Rep
De Rosa LI, Bianca P, Catania M, Kola K, Paolisi M, Brambilla Pisoni M, Farinone S, Maiucchi P, Citterio L, Petrone M, Rivera RF, Manunta P, Lanzani CL, Vezzoli G, Sciarrone Alibrandi MT.   +14 more
europepmc   +1 more source

Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand

ClinicoEconomics and Outcomes Research
Unchalee Permsuwan,1,2 Krit Leemasawat,3 Poukwan Arunmanakul1,2,4 1Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand; 2Center for Medical and Health Technology Assessment (CM-HTA), Department of ...
Permsuwan U, Leemasawat K, Arunmanakul P
doaj  

Mid-Term Impact of Kampo Goreisan in Patients with Congestive Heart Failure Receiving Tolvaptan-Incorporated Medical Therapy. [PDF]

J Clin Med
Hida Y, Imamura T, Kinugawa K.
europepmc   +1 more source

Efficacy and safety of tolvaptan in rapidly progressing autosomal dominant polycystic kidney disease: a single-center, prospective, single-arm study. [PDF]

Transl Androl Urol
Zhou L, Li W.
europepmc   +1 more source

Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study. [PDF]

Front Med (Lausanne)
Zhou L, Li W.
europepmc   +1 more source